| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Artemetin targets multiple enzymes and signaling pathways. It inhibits 5-lipoxygenase (5-LO), a key enzyme in the biosynthesis of leukotrienes, with an IC50 of 54.6 µM. It activates ERK1/2 and Akt signaling pathways, protecting endothelial function. It also scavenges peroxyl radicals, demonstrating antioxidant activity.
|
|---|---|
| ln Vitro |
In vitro, artemetin inhibits 5-lipoxygenase with an IC50 of 54.6 µM. It scavenges peroxyl radicals in a cell-free assay in a concentration-dependent manner. It activates ERK1/2 and Akt signaling, protecting endothelial function. These in vitro activities confirm its anti-inflammatory, antioxidant, and cytoprotective properties.
|
| ln Vivo |
In vivo, artemetin has been shown to protect endothelial function. However, specific details of in vivo efficacy studies are not extensively detailed in the available literature. The compound is a natural flavonoid with potential therapeutic applications for inflammation and oxidative stress-related diseases.
|
| Enzyme Assay |
The in vitro enzyme assay for artemetin measures its ability to inhibit 5-lipoxygenase activity. These cell-free assays use purified 5-LO and a substrate. The compound's inhibitory potency (IC50) is determined by measuring the reduction in enzyme activity. Artemetin shows an IC50 of 54.6 µM for 5-LO inhibition. Its antioxidant activity is assessed using cell-free radical scavenging assays.
|
| Cell Assay |
In vitro cellular assays for artemetin assess its effects on endothelial function and inflammation. Endothelial cells are treated with artemetin, and markers of endothelial function, such as ERK1/2 and Akt phosphorylation, are measured. Its anti-inflammatory effects are assessed in immune cells. These assays demonstrate the compound's functional activity in a relevant cellular context.
|
| Animal Protocol |
In vivo animal studies for artemetin have been conducted to assess its protective effects on endothelial function. However, specific details of these studies are not extensively detailed in the available literature. The compound is a natural product with potential for further research in inflammation and cardiovascular protection.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for artemetin are not extensively detailed in the available literature. As a natural flavonoid, its oral bioavailability may be limited. However, its in vivo efficacy suggests that it reaches sufficient systemic concentrations to exert its effects. The compound's pharmacokinetic properties would be important for its development as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for artemetin are not extensively detailed in the available literature. As a natural flavonoid, it is generally considered to have low toxicity. However, comprehensive toxicological studies would be required to establish its safety profile for therapeutic use. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
Artemetin belongs to the flavonoid class of compounds and is an ether compound. It has been reported to be found in verbena, arabiculata, and other organisms with relevant data.
Artemetin is a flavonoid found in Artemisia and other plants with anti-inflammatory, antioxidant, and antiapoptotic activities. It protects endothelial function through the activation of ERK1/2 and Akt. It inhibits 5-lipoxygenase with an IC50 of 54.6 µM. It is a research compound for studying inflammation, oxidative stress, and endothelial function and is not approved for clinical use. |
| Molecular Formula |
C20H20O8
|
|---|---|
| Molecular Weight |
388.3680
|
| Exact Mass |
388.115
|
| CAS # |
479-90-3
|
| PubChem CID |
5320351
|
| Appearance |
White to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
588.8±50.0 °C at 760 mmHg
|
| Flash Point |
208.9±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.608
|
| LogP |
2.55
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
591
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C2C([H])=C([H])C(=C(C=2[H])OC([H])([H])[H])OC([H])([H])[H])=C(C(C2=C(C(=C(C([H])=C12)OC([H])([H])[H])OC([H])([H])[H])O[H])=O)OC([H])([H])[H]
|
| InChi Key |
RIGYMJVFEJNCKD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H20O8/c1-23-11-7-6-10(8-12(11)24-2)18-20(27-5)17(22)15-13(28-18)9-14(25-3)19(26-4)16(15)21/h6-9,21H,1-5H3
|
| Chemical Name |
4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5-hydroxy-3,6,7-trimethoxy-
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :13~50 mg/mL (33.47~128.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5749 mL | 12.8743 mL | 25.7486 mL | |
| 5 mM | 0.5150 mL | 2.5749 mL | 5.1497 mL | |
| 10 mM | 0.2575 mL | 1.2874 mL | 2.5749 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
